279 related articles for article (PubMed ID: 27358895)
1. Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.
Kasi Loknath Kumar A; Weckbaugh B; Sirridge C; Woodroof J; Persons D; Kambhampati S
Stem Cell Investig; 2016; 3():3. PubMed ID: 27358895
[TBL] [Abstract][Full Text] [Related]
2. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review.
Ji J; Loo E; Pullarkat S; Yang L; Tirado CA
Exp Hematol Oncol; 2014; 3():8. PubMed ID: 24646765
[TBL] [Abstract][Full Text] [Related]
4. Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia.
Yamamoto K; Yakushijin K; Sanada Y; Kawamoto S; Matsuoka H; Minami H
J Clin Exp Hematop; 2015; 55(3):181-5. PubMed ID: 26763368
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.
Tanaka K; Oshikawa G; Akiyama H; Ishida S; Nagao T; Yamamoto M; Miura O
Oncol Lett; 2017 Jul; 14(1):97-102. PubMed ID: 28693140
[TBL] [Abstract][Full Text] [Related]
6. Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature.
Johnston RD; Sayedian FH; Mendiola C; Ehman W; Ortega V; Velagaleti GVN
Cancer Genet; 2022 Apr; 262-263():30-34. PubMed ID: 34974291
[TBL] [Abstract][Full Text] [Related]
7. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS; List AF
Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
10. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and
Hatzimichael E; Lagos K; Vassou A; Gougopoulou D; Papoudou-Bai A; Briasoulis E
Mol Clin Oncol; 2016 Jul; 5(1):23-26. PubMed ID: 27330758
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
12. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
13. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
14. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
Drusbosky LM; Cogle CR
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397113
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion.
Yang Y; Gao S; Fan H; Lin H; Li W; Wang J
Exp Ther Med; 2013 Sep; 6(3):803-807. PubMed ID: 24137269
[TBL] [Abstract][Full Text] [Related]
18. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
20. Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report.
Znoyko I; Stuart RK; Ellingham T; Winters J; Wolff DJ; Quigley DI
Cancer Genet Cytogenet; 2008 May; 183(1):64-8. PubMed ID: 18474300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
